Basilea Pharmaceutica (OTCMKTS:BPMUF – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Analyst Ratings
This is a breakdown of current ratings for Basilea Pharmaceutica and Novavax, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Basilea Pharmaceutica | 0 | 1 | 0 | 0 | 2.00 |
| Novavax | 3 | 1 | 5 | 1 | 2.40 |
Novavax has a consensus price target of $13.00, suggesting a potential upside of 39.34%. Given Novavax’s stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than Basilea Pharmaceutica.
Volatility & Risk
Valuation and Earnings
This table compares Basilea Pharmaceutica and Novavax”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Basilea Pharmaceutica | $280.43 million | 2.83 | $48.57 million | N/A | N/A |
| Novavax | $1.12 billion | 1.37 | $440.30 million | ($0.58) | -16.09 |
Novavax has higher revenue and earnings than Basilea Pharmaceutica.
Profitability
This table compares Basilea Pharmaceutica and Novavax’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Basilea Pharmaceutica | N/A | N/A | N/A |
| Novavax | -14.73% | -14.82% | 1.23% |
Institutional and Insider Ownership
53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Novavax beats Basilea Pharmaceutica on 10 of the 13 factors compared between the two stocks.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
